Standardized whole blood stimulation system proves superior reproducibility over PBMCsA new paper on improved methods for monitoring differential immune response activation was published in Volume 183 of the journal Clinical Immunology. Researchers report on a multi-center study in seven FOCIS Centers of Excellence to directly compare whole blood syringe-based system, TruCulture, to the current method of isolation of PBMCs for immunomonitoring. To compare intra and inter-center variability between PBMC and TruCulture stimulation, the blood of 152 healthy donors was both stimulated in whole blood assay and after isolation of PBMC, across multiple centers. Following exposure to LPS, anti-CD3/anti-CD28, or media alone, samples were analyzed using multi-analyte profiling (MAP) for 55 proteins at Myriad RBM’s CLIA-certified laboratory. Focusing on analytes that were induced in both TruCulture and PMBC stimulation, further analysis was based on the 35 commonly induced proteins.
Prevencio, Inc. has announced data published in The American Journal of Cardiology, on a new proteomic blood test that determines whether a person will have a heart attack, stroke, or other major adverse cardiac event (MACE) more accurately than the currently used clinical risk factors. A total of 927 patient samples were analyzed from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study undergoing coronary angiography.
3D Growth of Endothelial Cells During ISS Space Mission – The SPHEROIDS Project
The April 2017 issue of Biomaterials reports on an automated cell culture unit that was developed for the SpaceX CRS-ISS space mission that resulted in three dimensional growth of human endothelial cells in microgravity.
A spaceflight to the International Space Station, carried out in April – May 2016, included a study to examine endothelial cell (EC) behavior in respect to cellular proliferation and apoptosis under spaceflight conditions to examine the gravity dependency of EC tube formation.
Researchers led by Bernard Vanove of OSE Immunotherapeutics report in the December 7, 2016 issue of the Journal of Immunology on the first-in-human study of FR1041. OSE and collaborators at the University of Nantes and Janssen conducted a detailed phase I evaluation of safety, pharmacokinetics, pharmacodynamics and potency of FR104 in healthy volunteers.